3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Lymphoid
1
Gynecologic
1
Conditions
Warts
2
Melanoma
2
Hyperthermia
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Interventions
pembrolizumab
54
Nivolumab
50
Ipilimumab
28
Cyclophosphamide
16
binimetinib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
fludarabine
9
Radiosurgery
9
relatlimab
8
encorafenib
8
Opdualag
8
Biopsy
8
aldesleukin
7
Interleukin-2
7
atezolizumab
6
Immunotherapy
6
Blood Specimen Collection
6
cemiplimab
5
CTLA-4 Antigen
5
Bevacizumab
5
trametinib
4
fludarabine phosphate
4
dabrafenib
4
Temozolomide
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
spartalizumab
3
Surgical Procedures, Operative
3
Metformin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Melanoma
×
Solutions
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled
NCT07230613
2026-02-11
NEOREM-NEO-1
UNICANCER
Phase 2
Recruiting
50 enrolled